BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Senkevich K, Rudakou U, Gan-Or Z. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. Neuropharmacology 2021;202:108822. [PMID: 34626666 DOI: 10.1016/j.neuropharm.2021.108822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Hill EJ, Robak LA, Al-ouran R, Deger J, Fong JC, Vandeventer PJ, Schulman E, Rao S, Saade H, Savitt JM, von Coelln R, Desai N, Doddapaneni H, Salvi S, Dugan-perez S, Muzny DM, Mcguire AL, Liu Z, Gibbs RA, Shaw C, Jankovic J, Shulman LM, Shulman JM. Genome Sequencing in the Parkinson Disease Clinic. Neurol Genet 2022;8:e200002. [DOI: 10.1212/nxg.0000000000200002] [Reference Citation Analysis]
2 Sabnis RW. Novel N-Linked Isoquinoline Amides as LRRK2 Inhibitors for Treating Parkinson’s Disease. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.2c00263] [Reference Citation Analysis]
3 Pérez-Carrión MD, Posadas I, Solera J, Ceña V. LRRK2 and Proteostasis in Parkinson's Disease. Int J Mol Sci 2022;23:6808. [PMID: 35743250 DOI: 10.3390/ijms23126808] [Reference Citation Analysis]
4 Tsukita K, Sakamaki-tsukita H, Kaiser S, Zhang L, Messa M, Serrano-fernandez P, Takahashi R. Changes in the cerebrospinal fluid proteome precede and stratify the course of Parkinson’s Disease.. [DOI: 10.1101/2022.06.08.22276035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bezrukova AI, Basharova KS, Miliukhina IV, Timofeeva AA, Senkevich KA, Pchelina SN, Usenko TS. Reduced expression of neurogenesis genes as biomarkers of Parkinson's disease associated with mutations in the <i>GBA</i> gene: validation of the data analysis of transcriptome study. The Scientific Notes of the Pavlov university 2022;29:37-45. [DOI: 10.24884/1607-4181-2022-29-1-37-45] [Reference Citation Analysis]
6 Sabnis RW. 2-Aminoquinazolines as LRRK2 Inhibitors for Treating Parkinson's Disease. ACS Med Chem Lett 2022;13:775-6. [PMID: 35586430 DOI: 10.1021/acsmedchemlett.2c00155] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Senkevich K, Zorca CE, Dworkind A, Rudakou U, Somerville E, Yu E, Ermolaev A, Nikanorova D, Ahmad J, Ruskey JA, Asayesh F, Spiegelman D, Fahn S, Waters C, Monchi O, Dauvilliers Y, Dupré N, Greenbaum L, Hassin-baer S, Grenn FP, Chiang MSR, Sardi SP, Vanderperre B, Blauwendraat C, Trempe J, Fon EA, Durcan TM, Alcalay RN, Gan-or Z. GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease.. [DOI: 10.1101/2022.04.30.22274239] [Reference Citation Analysis]
8 Rodriguez-porcel F, Wyman-chick KA, Abdelnour Ruiz C, Toledo JB, Ferreira D, Urwyler P, Weil RS, Kane J, Pilotto A, Rongve A, Boeve B, Taylor J, Mckeith I, Aarsland D, Lewis SJG; the Lewy Body Dementias Clinical Trials Workgroup from the Lewy Body Dementias Professional Interest Area - Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART)+. Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. Transl Neurodegener 2022;11. [DOI: 10.1186/s40035-022-00299-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jia F, Fellner A, Kumar KR. Monogenic Parkinson’s Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing. Genes 2022;13:471. [DOI: 10.3390/genes13030471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Albanese F, Domenicale C, Volta M, Morari M. Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway. Biochem Soc Trans 2022;50:621-32. [PMID: 35225340 DOI: 10.1042/BST20211288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Fox SH, Brotchie JM. Special Issue on New therapeutic approaches to Parkinson disease. Neuropharmacology 2022;:108998. [PMID: 35150730 DOI: 10.1016/j.neuropharm.2022.108998] [Reference Citation Analysis]
12 Hill EJ, Robak LA, Al-ouran R, Deger J, Fong JC, Vandeventer PJ, Schulman E, Rao S, Saade H, von Coelln R, Doddapaneni H, Salvi S, Dugan-perez S, Muzny DM, Mcguire A, Liu Z, Gibbs R, Shaw C, Jankovic J, Shulman LM, Shulman JM. Genome sequencing in the Parkinson’s disease clinic.. [DOI: 10.1101/2021.11.23.21266755] [Reference Citation Analysis]